How long does taking enzalutamide generally extend your life?

Enzalutamide is an oral androgen receptor inhibitor mainly used to treat metastatic castration-resistant prostate cancer (mCRPC). As a new generation of anti-androgen drugs, enzalutamide inhibits the growth and spread of tumor cells by blocking the binding of androgens to their receptors. It is widely used clinically to delay disease progression and improve patient survival.

Multiple large clinical trials have shown that enzalutamide can significantly prolong the overall survival of patients. For example, the AFFIRM trial showed that in patients with mCRPC who had previously received chemotherapy, enzalutamide extended the median overall survival by approximately 4.8 months compared with placebo, demonstrating a significant survival benefit. In the PREVAIL trial, enzalutamide also showed the effect of prolonging overall survival for patients who did not receive chemotherapy. The median survival was approximately 5 months longer than that of the control group.

In addition, enzalutamide not only prolongs survival time, but also improves patients' quality of life and relieves symptoms, which is of great significance for the comprehensive treatment of patients with advanced prostate cancer. It is often used in combination with other treatments, such as castration and supportive care of bone metastases, to achieve more comprehensive disease control.

It should be pointed out that the specific life-prolonging time of enzalutamide varies depending on individual patient differences, disease stage, pre-treatment status, and combined medication and other factors. Some patients may achieve longer survival, while for other patients, the prolongation effect is limited due to the extent of disease invasion. Overall, enzalutamide provides an important treatment option for patients with metastatic castration-resistant prostate cancer, significantly improving patient survival outcomes.

Reference materials:https://www.drugs.com/